Cravath Reps J&J In $2.3B Bid For Crucell
Drugmaker Johnson & Johnson, which owns 17.9 percent of the outstanding shares of Crucell NV, made a formal bid Tuesday to buy the remainder of the Dutch biotechnology firm for €1.75...To view the full article, register now.
Already a subscriber? Click here to view full article